Our results in a micrometastatic PC model demonstrate significant survival benefit and an even higher therapeutic ratio than the corresponding PSMA-targeting α-particle emitter 211At-PSMA-6 16, confirming the potential for Auger emitter therapy in treatment of micrometastatic disease. Here, FOLH1 is linked to pachyonychia congenita.